Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States

Othman, Noordin; Vitry, Agnes I.; Roughead, Elizabeth E.
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p294
Academic Journal
Background: Journal advertising is used by pharmaceutical companies to disseminate medicine information to doctors. The quality of claims, references and the presentation of risk results in Australia and the US has been questioned in several studies. No recent evidence is available on the quality of claims, references and the presentation of risk results in journal advertising in Australia and the US and no Malaysian data have been published. The aim of this study was to compare the quality of claims, references and the presentation of risk results in journal advertising in these three countries. Methods: A consecutive sample of 85 unique advertisements from each country was selected from journal advertising published between January 2004 to December 2006. Claims, references and the presentation of risk results in medical journal advertising were compared between the three countries. Results: Less than one-third of the claims were unambiguous claims (Australia, 30%, Malaysia 17%, US, 23%). In Malaysia significantly less unambiguous claims were provided than in Australia and the US (P < 0.001). However, the unambiguous claims were supported by more references than other claims (80%). Most evidence was obtained from at least one randomized controlled trial, a systematic review or meta-analysis (Australia, 84%, Malaysia, 81%, US, 76%) with journal articles being the most commonly cited references in all countries. Data on file were significantly more likely to be cited in the US (17%) than in Australia (2%) and Malaysia (4%) (P < 0.001). Advertisements that provided quantitative information reported risk results exclusively as a relative risk reduction Conclusions: The majority of claims were vague suggesting poor quality of claims in journal advertising in these three countries. Evidence from a randomized controlled trial, systematic review or meta-analysis was commonly cited to support claims. However, the more frequent use of data that have not been published and independently reviewed in the US compared to Australia and Malaysia raises questions on the quality of references in the US. The use of relative rather than absolute benefits may overemphasize the benefit of medicines which may leave doctors susceptible to misinterpreting information.


Related Articles

  • Forcing Pharma's Hand. Varmazis, Catherine // Bio-IT World;Jul/Aug2007, Vol. 6 Issue 6, p38 

    The article focuses on the issues concerning the policies issued by the International Committee of Medical Journal Editors (ICMJE). The policies were issued following criticisms on the hesitance of pharmaceutical companies to register ongoing clinical trials. According to ICMJE, the update on...

  • Ghosts still present in the medical machine. Jones, Nicola // Nature;9/17/2009, Vol. 461 Issue 7262, p325 

    The article reports that ghostwriting in medical literature remains, despite the policy changes in drug-company and efforts of journals to cut down the practice in the U.S. It states that the ghostwriting, is a practice that involves pharmaceutical companies designing and paying for studies or...

  • Ghost Management: How Much of the Medical Literature Is Shaped Behind the Scenes by the Pharmaceutical Industry? Sismondo, Sergio // PLoS Medicine;Sep2007, Vol. 4 Issue 9, pe286 

    Sismondo discusses how pharmaceutical companies and their agents shape multiple steps in the research, analysis, writing, and publication of articles.

  • Drug firm research has lower impact.  // GP: General Practitioner;10/3/2012, p16 

    The article reports on the study which suggests that doctors are less likely to act on the findings of research funded by pharmaceutical companies in the U.S. It indicates that doctors were 37% less likely to consider prescribing a drug on the basis of studies from pharmaceutical companies. The...

  • McMaster PLUS: A Cluster Randomized Clinical Trial of an Intervention to Accelerate Clinical Use of Evidence-Based Information from Digital Libraries. Haynes, R. Brian; Holland, Jennifer; Cotol, Chris; McKinlay, R. James; Wilczynski, Nancy L.; Walters, Leslie A.; Jedras, Dawn; Parrish, Rick; McKibbon, K. Ann; Garg, Amit; Walter, Stephen D. // Journal of the American Medical Informatics Association;Nov/Dec2006, Vol. 13 Issue 6, p593 

    Background: Physicians have difficulty keeping up with new evidence from medical research. Methods: We developed the McMaster Premium LiteratUre Service (PLUS), an internet-based addition to an existing digital library, which delivered quality- and relevance-rated medical literature to...

  • Pharmaceutical marketing strategy: Lessons from the medical literature. Black, Iain // Journal of Medical Marketing;Apr2005, Vol. 5 Issue 2, p119 

    This article presents information on research work related to pharmaceutical marketing strategy. The author provides an insight into representative based education. This has been chosen because it represents a core pharmaceutical marketing strategy. A number of researchers have demonstrated the...

  • Medical journals and pharmaceutical companies: uneasy bedfellows. Smith, Richard // BMJ: British Medical Journal (International Edition);5/31/2003, Vol. 326 Issue 7400, p1202 

    Focuses on the funding of medical journals by pharmaceutical companies, and questions whether this funding is corrupting the journals. Dependence of free newspapers for physicians and medical journals on income from pharmaceutical advertising; Opinion that drug advertising is often misleading;...

  • Biomedical Industrial Sponsorship and Its Impact on the Medical Literature. Morris, Peter J. // World Journal of Surgery;Aug2006, Vol. 30 Issue 8, p1371 

    The article focuses on the issue of the influence of biomedical industrial sponsorship on medical literature. In order to bring a new drug onto the market clinical trials are conducted. These trials take place in clinics in both university and nonuniversity institutions and, for the most part,...

  • Drug giants fail to name compounds in trial database. Wadman, Meredith // Nature;6/2/2005, Vol. 435 Issue 7042, p548 

    The article reports that an international group of medical editors is challenging several leading pharmaceutical companies, saying that their reporting of clinical trials is deliberately incomplete. They argue that leading pharmaceutical companies are obeying the letter but not the spirit of a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics